(Q28242387)

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Pharmacogenetic phenotyping and genotyping. Present status and future potential.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Polymorphism of dextromethorphan oxidation in a French population

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Impaired oxidation of debrisoquine in patients with perhexiline liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

A proposed mechanism for chlorpromazine jaundice--defective hepatic sulphoxidation combined with rapid hydroxylation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Genetically determined oxidation polymorphism and drug hepatotoxicity. Study of 51 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Molecular genetics of the debrisoquin-sparteine polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Genetic polymorphism of S-mephenytoin hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Genetic control of isoniazid metabolism in man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

An alternative test for acetylator phenotyping with caffeine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

A rapid method for determination of acetylation phenotype using dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Molecular mechanism of slow acetylation of drugs and carcinogens in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Diverse point mutations in the human gene for polymorphic N-acetyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Genetic aspects of the polymodally distributed sulphoxidation of S-carboxymethyl-L-cysteine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

The deficiency of sulfoxidation of S-carboxymethyl-L-cysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

High incidence of poor sulfoxidation in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Glutathione synthetase-deficient lymphocytes and acetaminophen toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Predisposition to phenytoin hepatotoxicity assessed in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Halothane hepatitis. Detection of a constitutional susceptibility factor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Familial occurrence of hypersensitivity to phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Metabolic activation of the tricyclic antidepressant amineptine--I. Cytochrome P-450-mediated in vitro covalent binding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Metabolic activation of the tricyclic antidepressant amineptine--II. Protective role of glutathione against in vitro and in vivo covalent binding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome P-450.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Interactions between immunogenic peptides and MHC proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

HLA A and B Locus Antigens in Patients with Unexplained. Hepatitis following Halothane Anaesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

HLA antigens in patients with unexplained hepatitis following halothane anesthesia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021

Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980492-8

7 January 2021